What does semaglutide actually cost? Two markets, two very different answers

Two markets, two answers

Search for what semaglutide costs and you'll get numbers from $45 to well over $1,000. Both ends are real, which is why the search is so frustrating.

The spread isn't because someone's lying. It's because at least two entirely separate markets sell something called semaglutide, and they aren't selling the same thing.

Here's what we actually recorded.

The prescription route

We track official self-pay programs as dated snapshots. For Wegovy, sold through the manufacturer's pharmacy channel and observed on 13 July 2026:

Both require a valid prescription and program eligibility. Taxes, fees, and program terms apply on top.

The research-vendor route

In our price market, as of the 25 July 2026 check, semaglutide is listed by 2 vendors at $45.00 to $125.00 per package.

That's it. Two vendors, seven individual offers, in a market where we track 706 offers across 60 compounds.

The $199 is not the price

Look again at that first table, because it contains the single most useful thing on this page.

$199 becomes $349 on the third fill. That's a 75% increase, built into the offer from the start.

If you budget from the number in the advertisement, your third month costs $150 more than you planned. Annualise the intro price and you understate the year by roughly $1,650, assuming nothing else changes.

Nothing here is hidden. The condition is published, and we recorded it alongside the price because a price without its condition isn't information.

That distinction also has teeth. An introductory rate advertised in a way that obscures what happens on renewal is the kind of pricing claim advertising regulators take an interest in.²

This is the exact failure mode we describe in why weight-care pricing resists honest comparison: four products wearing the same dollar sign. Now you can see it in one manufacturer's own two rows.

Why the $45 isn't the bargain it looks like

The gap between $45 and $349 looks like an obvious arbitrage. It isn't, and the reasons are worth being precise about.

They're different products. One is an approved finished product in a pre-filled pen, dispensed by a pharmacy against a prescription. The other is material sold labelled for research, not authorized for human use.³

There's a third category you'll meet while shopping, sitting between those two: compounded preparations. A compounded product is prepared by a pharmacy rather than approved as a finished product, and it comes with its own separate rules and its own price band.¹

The units don't match. $349 buys a stated 28-day supply. $45 buys a package, and what's in it is a separate question from what it costs.

One has a clinical relationship attached. Prescriber, monitoring, and somewhere to go when something goes wrong. That's not free and it isn't priced separately.

And the cheap one is nearly unverifiable. Across the 117 records in our testing ledger, exactly 2 are semaglutide. For the compound with the lowest sticker price, there's almost no published lab evidence about what ships.

We keep prescription snapshots in a table separate from research listings for exactly this reason. Sorting them together would make the cheapest row look like the best deal, when it's a different category of thing.

What the numbers do tell you

Comparison isn't useless. It's just narrower than people want.

Use the range to spot the outliers. Knowing the research market runs $45 to $125 means a $400 listing needs explaining.

Use the intro-versus-standard gap to budget honestly. Assume the standard price, not the offer.

Use cost per milligram, never per package. Two listings aren't comparable until quantity is fixed, which is why our market normalizes and dates every observation.

And treat any undated figure as expired. Including these. The prescription snapshots here were read on 13 July 2026 and the vendor range on 25 July 2026, and both will move.

Where this leaves the question

There isn't one price for semaglutide, and anyone quoting you a single number is either describing one narrow route or selling something.

What there is: a published self-pay path at $199 rising to $349 per 28-day supply, and a research-vendor range of $45 to $125 per package for material that isn't authorized for human use and that almost nobody has published a lab test on.

Those aren't two prices to choose between. They're two different decisions, and only one of them is mainly about money.

More on the compound itself in what semaglutide is, and its profile with graded outcomes at semaglutide.